Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study
- Lampertico P.
- Berg T.
- Buti M.
- Pathil A.
- Petersen J.
- Ryder S. D.
- Zoulim F.
- Botros I.
- Flaherty J. F.
- Jump B.
- Op den Brouw M. L.
- van Troostenburg A.
- Ramroth H.
- Bourliere M.
- De Ledinghen V.
- Riachi G.
- Zoulim F.
- Loustaud-Ratti V.
- Tran A.
- Larrey D.
- Dumortier J.
- Leroy V.
- Metivier S.
- Sellier P.
- Mauss S.
- Peterson J.
- Berg T.
- Schiefke I.
- Niederau C.
- Teuber G.
- Goeser T.
- Jung M. C.
- Grambihler A.
- Pathil-Warth A.
- Sprinzl K.
- Von der Ohe M.
- Antoni C.
- Weigand K.
- Andreone P.
- Lampertico P.
- Di Marco V.
- Madonia S.
- Puoti M.
- Santantonio T.
- Vigano M.
- Ciancio A.
- D'Offizi G.
- Pirisi M.
- Buti M.
- Suarez Garcia E.
- Pascasio Acevedo J. M.
- Andrade R.
- Gea F.
- Serra Desfilis M. A.
- Molina Perez E.
- Manzano Alonso M.
- Carrion J. A.
- Aoufi Rabih S.
- Planas M. M.
- Ryder S.
- Agarwal K.
- Ustianowski A.
- Aspinall R.
- Kennedy P.
- Geretti A. M.
- McCorry R.
- Foxton M.
- Healy B.
DOIAbstract
Background: Limited data exist regarding tenofovir disoproxil fumarate (TDF) safety and effectiveness in chronic hepatitis B virus–infected (CHB) patients with renal impairment (RI). Aims: To compare real-world data on renal safety and effectiveness of TDF vs entecavir (ETV) in CHB patients with moderate-to-severe RI. Methods: Retrospective, non-interventional, cohort study analysing medical records for TDF/ETV-treated CHB patients (54 European centres). Included patients experienced moderate-to-severe RI (creatinine clearance 20-60 mL/min [Cockcroft-Gault]) either before TDF/ETV initiation (‘before’ subgroup [baseline = treatment initiation]) or after TDF/ETV initiation (‘after’ subgroup [baseline = first RI occurr...
Add to ORKG